Clearmind Medicine Inc., a biotechnology company, has filed an amended annual report for the fiscal year ended October 31, 2023. The amendment, submitted to the United States Securities and Exchange Commission, includes certifications by the company's principal executive officer and principal financial officer, which were previously omitted. The company's common shares are listed on The Nasdaq Stock Market under the symbol CMND, with 607,337 common shares outstanding as of the report's fiscal year-end. Clearmind Medicine is classified as an emerging growth company and a non-accelerated filer according to the SEC's definitions. The company has complied with all reporting requirements of the Exchange Act for the past 12 months and has submitted all required Interactive Data Files. The financial...Show More

Clearmind Medicine Inc., a biotechnology company, has filed an amended annual report for the fiscal year ended October 31, 2023. The amendment, submitted to the United States Securities and Exchange Commission, includes certifications by the company's principal executive officer and principal financial officer, which were previously omitted. The company's common shares are listed on The Nasdaq Stock Market under the symbol CMND, with 607,337 common shares outstanding as of the report's fiscal year-end. Clearmind Medicine is classified as an emerging growth company and a non-accelerated filer according to the SEC's definitions. The company has complied with all reporting requirements of the Exchange Act for the past 12 months and has submitted all required Interactive Data Files. The financial statements included in the filing adhere to International Financial Reporting Standards as issued by the International Accounting Standards Board. The report does not indicate any restatements of previously issued financial statements or corrections of errors. The company's auditor, Brightman Almagor Zohar & Co., is based in Tel Aviv, Israel. The amendment also includes a list of exhibits related to the company's articles of association, securities descriptions, various agreements, and certifications. Clearmind Medicine's business development and future plans were not detailed in this amendment.